Please use this identifier to cite or link to this item:
Title: Palliative and Supportive Care Prescribing Considerations Around QT Prolongation Risk in the Context of COVID-19 (Coronavirus Disease 2019) Management
Austin Authors: Wong, Aaron B ;Keith, Claire ;Gregory, Heidi ;Liew, David F L 
Affiliation: Palliative Care
Clinical Pharmacology and Therapeutics
Issue Date: 22-Sep-2020
Date: 2020
Publication information: Journal of Pain & Palliative Care Pharmacotherapy 2020; online first: 22 September
Abstract: COVID-19 brings with it unprecedented challenges in clinical management. An important component of care is the provision of safe and effective symptom control. Given the emerging literature reporting on the risk of QT prolongation and arrhythmias associated with COVID-19 disease and experimental therapies, we highlight some considerations for the prescribing of palliative care medications in this context. Based on the experience gained from palliative care referrals at our institution prior to and during the COVID-19 pandemic, and in collaboration with our clinical pharmacology colleagues, we outline some general prescribing principles which may assist with weighing the risks and benefits of prescribing symptomatic medications in and beyond the current pandemic.
DOI: 10.1080/15360288.2020.1814481
ORCID: 0000-0003-1284-9709
Journal: Journal of Pain & Palliative Care Pharmacotherapy
PubMed URL: 32960661
Type: Journal Article
Subjects: COVID-19
QT/QTc prolongation
drug interactions
palliative care
symptom management
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 12, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.